DCLA
NVS icon

Douglas C. Lane & Associates’s Novartis NVS Stock Holding History

Douglas C. Lane & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$45.7M Sell
592,289
-11,528
-2% -$916K 1.24% 29
2015
Q3 		$49.7M Sell
603,817
-3,323
-0.5% -$296K 1.41% 21
2015
Q2 		$53.5M Sell
607,140
-4,030
-0.7% -$370K 1.44% 19
2015
Q1 		$54M Sell
611,170
-8,323
-1% -$738K 1.42% 19
2014
Q4 		$51.4M Sell
619,493
-900
-0.1% -$74.6K 1.39% 19
2014
Q3 		$52.3M Buy
620,393
+1,635
+0.3% +$132K 1.56% 17
2014
Q2 		$50.2M Sell
618,758
-3,425
-0.6% -$269K 1.52% 16
2014
Q1 		$47.4M Buy
622,183
+10,483
+2% +$764K 1.52% 17
2013
Q4 		$44.1M Buy
611,700
+646
+0.1% +$44.9K 1.46% 19
2013
Q3 		$42M Buy
611,054
+2,595
+0.4% +$172K 1.53% 14
2013
Q2 		$38.6M Buy
+608,459
New +$39.6M 1.5% 14

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
IC
Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Douglas C. Lane & Associates's NVS Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Novartis (NVS) stake by 1.9% in Q4 2015, selling an estimated $916K and leaving 592,289 shares worth $45.7M. The position accounts for 1.24% of the portfolio, ranked #29.

Douglas C. Lane & Associates first reported a position in NVS in Q2 2013 and has held it in 11 quarters since. The position peaked at $54M in Q1 2015. 927 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

  • Douglas C. Lane & Associates held 592,289 shares of Novartis worth $45.7M as of Q4 2015.
  • Douglas C. Lane & Associates sold 11,528 Novartis shares in Q4 2015, an estimated $916K.
  • Novartis made up 1.24% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #29 holding.
  • Douglas C. Lane & Associates first reported a position in Novartis in Q2 2013 and has held it in 11 quarters since.
  • Douglas C. Lane & Associates's Novartis position peaked at $54M in Q1 2015.
  • 927 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.